Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05202119 · ClinicalTrials.gov registry record · NA
Empower: tDCS for Major Depressive Disorder at Home
A NA study of Major Depressive Disorder, sponsored by Flow Neuroscience AB.
- Completed
- Registry status
- NA
- Development phase
- 174
- Enrollment target
- 2
- Study locations
NCT05202119: Completed NA study of Major Depressive Disorder, sponsored by Flow Neuroscience AB.
NCT05202119 is a NA study of Major Depressive Disorder that has completed, run by Flow Neuroscience AB. The registered enrollment target is 174 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05202119, a NA study of Major Depressive Disorder, has completed, sponsored by Flow Neuroscience AB.
- COMPLETED
- Registry status
- NA
- Development phase
- 174 participants
- Enrollment target
- 2
- Study locations
Study Summary
A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home. Participants perform up to 36 tDCS sessions by themselves without supervision during a blinded 10-week phase, and then 30 more sessions during an unblinded open-label phase.
Primary Outcome
Comparison of mean score change based on HDRS-17 scores of the two arms at 10 weeks. Mean score change is calculated as change in score from baseline to week 10. HDRS-17 is a clinician rated diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Range of scores: 0 to 52. Higher scores represent greater severity of depressive symptoms.
Conditions Studied
Interventions
- DEVICE Transcranial direct current stimulation
- DEVICE Sham Transcranial direct current stimulation
Study Locations (2)
Texas
- UT Health Science Center - Houston
Other
- School of Psychology, University East London - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2023-08-31 |
| Phase | NA |
What the finished NCT05202119 record still lists
NCT05202119 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Transcranial direct current stimulation is the first listed.
NCT05202119 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT05202119 about?
NCT05202119 is a clinical study titled "Empower: tDCS for Major Depressive Disorder at Home". A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home. Participants perform up to 36 tDCS sessions by themselves without supervision during a blinded 10-we...
What is the current status of trial NCT05202119?
This trial is currently completed. It is a NA study. The enrollment target is 174 participants. The study started on 2022-05-01. Estimated completion is 2023-08-31.
What conditions does trial NCT05202119 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05202119?
The interventions under investigation include: Transcranial direct current stimulation (DEVICE), Sham Transcranial direct current stimulation (DEVICE).
Who is sponsoring clinical trial NCT05202119?
This trial is sponsored by Flow Neuroscience AB, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05202119 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05202119's enrollment target sits among peer trials
174 88th of 282 higher than 194 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI